Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Phase 2

Terminated

• Conditions: Carcinoma, Non-Small-Cell Lung
• Interventions: Drug: Vactosertib 300 mg BID and pembrolizumab 200 mg IV

• Registration Number: NCT04515979
• Lead Sponsor: MedPacto, Inc.

Brief Summary

This is Phase 2, open label, multi-center study to assess safety and efficacy of vactosertib in combination with pembrolizumab as 1st line treatment for subjects with advanced or metastatic, PD-L1 positive, non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and in whom EGFR, ALK, BRAF, ROS1-directed therapy is not indicated.

Detailed Description

Approximately 55 NSCLC subjects with PD-L1 tumor proportion score (TPS) ≥ 1% are expected to be enrolled in this study. Subjects' TPS will be determined by PD-L1 IHC 22C3 pharmDx assay performed according to local laboratory regulations prior to study enrollment.

Subjects who received adjuvant or neoadjuvant therapy are permitted onto the study if the therapy was completed at least 12 months prior to the development of metastatic disease.

Eligible subjects will receive:

• Vactosertib 300 mg orally (PO) BID for 5 days with 2 days off period (5 days on/2days off) and pembrolizumab 200 mg IV on Day 1 of every 3-week cycle (Q3W).

Study Timeline

• Study First Submitted: 2020-08-11
• Study First Submitted QC: 2020-08-13
• Study First Posted: 2020-08-17
• Study Start: 2020-12-17
• Primary Completion: 2024-08-05
• Study Completion: 2024-08-05
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-04
• Last Update Posted: 2024-12-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 11

Inclusion Criteria

• Have a histologically- or cytologically-documented NSCLC advanced or stage IV lung cancer
• Have confirmation that EGFR, ALK, BRAF, ROS1-directed therapy is not indicated
• Have measurable disease based on RECIST 1.1
• PD-L1 expression is ≥1% as determined by the PD-L1 IHC 22C3 pharmDx assay
• Have a life expectancy of at least 3 months.
• ECOG 0 or 1
• Subjects must be able to swallow tablets and absorb vactosertib.
• Have adequate organ function as indicated by the following laboratory values in

Exclusion Criteria

• Is currently participating in a study of an investigational agent
• Has received prior systemic cytotoxic chemotherapy for metastatic disease/ antineoplastic biological therapy /Had major surgery / radiation therapy to the lung
• Has received a live vaccine within 30 days prior to the first dose of study drug.
• Is taking prohibited medications
• Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• Had a severe hypersensitivity reaction to treatment with another mAb previously.
• Has severe hypersensitivity to vactosertib and/or any of its excipients

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
vactosertib+Pembrolizumab	Vactosertib 300 mg BID and pembrolizumab 200 mg IV	Vactosertib (5days on and 2days off) Pembrolizumab 200mg Q3Weeks

Primary Outcome Measures

Name	Time	Method
ORR per RECIST 1.1	From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years	ORR in PD-L1≥1% and PD-L1≥50% population per RECIST 1.1 by investigators

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of